title: Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
abstract: OBJECTIVE
  This multicenter study describes the effectiveness of eribulin in current practice.
  
  
  METHODS
  In total, 78 patients with advanced metastatic breast cancer, previously treated with two or more chemotherapy lines were enrolled.
  
  
  RESULTS
  The median duration of response and disease stability were 7.5 (5.4-9.5) and 8.9 (6.2-11.6) months, respectively, with a clinical benefit (CB) at 6 months in 41% of patients. CB in visceral and nonvisceral metastases were 72.7 and 88.9%, respectively. Eribulin was active also in brain metastases, with 47% CB. The activity was shown in all biological subtypes. Toxicities were manageable.
  
  
  CONCLUSIONS
  Our study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic sites.
authors: Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy.
authors: Alessandra
authors: A
authors: Fabi
authors: Luca
authors: L
authors: Moscetti
authors: Mariangela
authors: M
authors: Ciccarese
authors: Miriam
authors: M
authors: Caramanti
authors: Nello
authors: N
authors: Salesi
authors: Nicla
authors: N
authors: La Verde
authors: Michelangelo
authors: M
authors: Russillo
authors: Daniele
authors: D
authors: Generali
authors: Giuseppina
authors: G
authors: Scandurra
authors: Sabrina
authors: S
authors: Vari
authors: Umberto
authors: U
authors: Pacetti
authors: Francesco
authors: F
authors: Cognetti
authors: Diana
authors: D
authors: Giannarelli
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D003131:Combined Modality Therapy; D019468:Disease Management; D018450:Disease Progression; D005260:Female; D005663:Furans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D019233:Retreatment; D016896:Treatment Outcome; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides
keywords: brain metastases; eribulin; metastatic breast cancer; triple negative